VIMPAT® is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
VIMPAT is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
IMPORTANT SAFETY INFORMATION
VIMPAT is associated with important warnings and precautions including suicidal behavior and ideation, dizziness and ataxia, cardiac rhythm and conduction abnormalities, syncope, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multi-organ hypersensitivity.
In the adult adjunctive placebo-controlled trials for partial-onset seizures, the most common adverse reactions (≥10% and greater than placebo) were dizziness, headache, nausea, and diplopia. In the adult monotherapy clinical trial, adverse reactions were generally similar to those observed and attributed to drug in adjunctive placebo-controlled trials, with the exception of insomnia (observed at a higher rate of ≥2%). Pediatric adverse reactions were similar to those seen in adult patients.
Primary Generalized Tonic-Clonic Seizures
In the adjunctive therapy placebo-controlled trial for primary generalized tonic-clonic seizures, the adverse reactions were generally similar to those that occurred in the partial-onset seizures trials. The adverse reactions most commonly reported were dizziness, somnolence, headache, and nausea.
VIMPAT is a Schedule V controlled substance.
Since being launched in the U.S. for adult adjunctive therapy in 2009, UCB has continued to bring VIMPAT to more patients with partial-onset seizures. VIMPAT is approved for monotherapy and adjunctive therapy in adults and children (ages 4 and older), with >500,000 patient exposures in the U.S.1
IN THE U.S.
Launched for adult
Approved for adult
Approved for monotherapy and adjunctive therapy in
CHILDREN ≥4 YEARS OF AGE
YEARS OF COMMITMENT TO PATIENTS—AND COUNTING
PATIENT EXPOSURES IN THE U.S.1
Simple dose conversion between formulations.
With VIMPAT, you have administration options. Choose between tablets, oral solution, and intravenous (IV) injection when oral administration is temporarily not feasible.
(Formulations not shown at actual size.)
UCB IS COMMITTED TO MAKING TREATMENT ACCESSIBLE
OF COMMERCIAL AND MEDICAID PATIENTS HAVE FORMULARY ACCESS TO VIMPAT® (LACOSAMIDE), AND MOST HAVE UNRESTRICTED ACCESS1
WE'RE ALSO COMMITTED TO MAKING TREATMENT AFFORDABLE
Nearly 75% of eligible commercial patients* paid as little as $20 per 30-day supply of VIMPAT® with the VIMPAT Patient Savings Program1
Patients are responsible for a minimum of $20 out-of-pocket expense per 30-day supply. This card will then be applied toward any remaining out-of-pocket expense up to a maximum of $1300. If you have any questions regarding your eligibility or benefits or if you wish to discontinue your participation, call the VIMPAT Savings Program at 1-888-786-5879 (8:30 AM – 5:30 PM EST, Monday-Friday and 8:30 AM – 2:30 PM EST, Saturday). This savings card is not valid for use by patients who are covered by any federally funded or state-funded healthcare program (including, but not limited to, Medicare [Part D and Medigap], Medicaid, any state pharmaceutical assistance program, TRICARE, VA, or DoD). Offer good only in the US, including Puerto Rico. This card may only be used with a valid VIMPAT prescription at the time the prescription is filled by the pharmacist and dispensed to the patient. The maximum annual benefit amount is $1300 per calendar year. Void where prohibited by law, taxed, or restricted. This offer cannot be combined with any other promotional offer. UCB, Inc. reserves the right to rescind, revoke, or amend this offer without notice at any time. No cash value. Not eligible for sale, purchase, trade, or counterfeit.
STRIKE A BALANCE FOR YOUR PATIENTS. CHOOSE VIMPAT.
You can request samples through your UCB sales representative or by
calling ucbCARES® at 1-844-599-CARE (2273).
- Data on file. UCB, Inc.